Read Avidity’s Community Letter:
The post Avidity’s trial for individuals with Duchenne amenable to skipping exon 45 is aiming to start in the first half of 2027 appeared first on CureDuchenne.
Categories
Recent Posts
- Dyne hopes to bring new treatment for DM1 to US market in 2028
- Avidity’s trial for individuals with Duchenne amenable to skipping exon 45 is aiming to start in the first half of 2027
- MDA Ambassador Guest Blog: My Myasthenia Gravis Voyage
- PPMD Joins FDA Leadership for Rare Disease Roundtable
- Entrada shares updates on Duchenne programs, including initiation of Cohort 2 in UK and EU trial skipping exon 45
Archive
- June 2026
- May 2026
- April 2026
- March 2026
- February 2026
- January 2026
- December 2025
- November 2025
- October 2025
- September 2025
- August 2025
- July 2025
- June 2025
- May 2025
- April 2025
- March 2025
- February 2025
- January 2025
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- February 2024
- January 2024